Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 7th, 2025
1:05 PM - 4:35 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Samara Stevens, ND; Douglas Carr, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD; Jeanne Savage, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Michael Yu, DC; Kyle Hamilton

Audience: Jessica Jay*, Vertex; Aaron Feyos*, BMS; Christopher Gallardo, Intra-Cellular Therapeutics; Paul Thompson, Alkermes; Mae Kwong, Soleno Therapeutics; Parisa Salehi, MD, UW; Oliver Passemard, PWSA-USA; Chi Kohlhoff, Madrigal; Jenna Doerr, Artia; Jen Davis, Gilead; Matt Prokop, ADA; Reina Rittman, Intra-Cellular; Michael Pannell, Alkermes; ; Aliethia McLeod, Trillium; William Lam, Madrigal; Michelle Bice, Soleno; Chris Ferrin, IHN; Ann Nelson, Vertex; Tammi Ocumpaugh, Otsuka; Rosalie Elliott, Umpqua Health; Heidi Gullett, OHA HERC; Lee Stout, Chiesi; Amy Hale, J&J; Shauna Wick, Trillium; Marc Parker, VS Health Group; Jill Carroll, BMS; Norm Navarro, Providence Health; Divine Marcelo, Amgen; Erin Nowak, AbbVie; Melissa Roy, Otsuka; Michelle Garcia, Moda Health; Rochelle Yang, Teva; Daria Meleshkina, Moda/EOCCO; Ben Schwartz; Mark Kantor, AllCare; Brett Freund; Cody Traweek, Providence; Anne Murray, BMS; Audaire Health; S.Fritts, Acadia

(*) Provided verbal testimony

I. CALL TO ORDER

A. Roll Call & Introductions
- Meeting called to order at approx. 1:05 p.m., introductions by Committee and staff

B. Conflict of Interest Declaration – no new conflicts of interest were declared

C. Approval of Agenda and June Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor

D. Department Update provided by Andrew Gibler, PharmD

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

II. CONSENT AGENDA TOPICS

A. Buprenorphine Policy Evaluation
Recommendation:
- No policy changes are recommended

B. Quarterly Utilization Report

C. Oncology Prior Authorization (PA) Updates
Recommendation:
- Add: Avmapki™ Fakzynja™ Co-Pack (avutometinib and defactinib); Lynozyfic™ (invoseltamab-gcpt); Penpulimabkcqx; Zegfrovy™ (sunvozertinib); Ibtrozi™ (taletrectinib); Emrelis™ (telisotuzumab vedotin-tllv); and Grafapex™ (treosulfan) to Table 1 in the Oncology Agents PA criteria

D. Orphan Drug Policy Updates
Recommendation:
- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Imaavy™ (nipocalimab-aahu); and Rezzayo® (rezafungin)based on their FDA-approved label
ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report: Lan Starkweather, PharmD

B. RetroDUR Report: Dave Engen, PharmD

C. Oregon State Drug Review: Kathy Sentena, PharmD
1. Off-label uses of GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists
2. Pharmacologic Management of Vasomotor Menopausal Symptoms

IV. OLD BUSINESS

A. Gene Therapy for Sickle Cell Disease: Sara Fletcher, PharmD
Recommendation:
- Modify Sickle Cell Disease PA criteria to allow the state to participate in the Cell and Gene Therapy Access Model for sickle cell disease gene therapies
- Retire Lovotibeglogene Autotemcel PA criteria
- Make exagamglogene autotemcel (Casgevy®) and lovotibeglogene autotemcel (Lyfgenia™) preferred
Public Comment: Jessica Jay, Vertex
ACTION: Motion to approve, 2nd, all in favor

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

V. NEW BUSINESS

A. P&T Evidence Methods and Procedures for Non-drug Items: Sara Fletcher, PharmD
Recommendations:
- Update Operating Procedures as proposed
- Update Review Standards and Methods for Quality Assessment of Evidence as proposed
ACTION: Motion to approve, 2nd, all in favor

B. New Drug Policy Update: Sarah Servid, PharmD
Recommendations:
- No policy changes are recommended
ACTION: Motion to approve, 2nd, all in favor

C. Second-generation Antipsychotics Class Update and New Drug Evaluation: Deanna Moretz, PharmD
Recommendations:
- Based on review of recent clinical evidence, no changes to the Preferred Drug List (PDL) are recommended for the First Generation (FGA), Second Generation (SGA), or Parenteral antipsychotics
- Evaluate comparative costs in executive session
Public Comment: Aaron Feyos, BMS; Christopher Gallardo, Intra-Cellular; Paul Thompson, Alkermes
ACTION: Motion to approve, 2nd, all in favor

D. Modafinil and Armodafinil Drug Use Evaluation: Sarah Servid, PharmD
Recommendations:
- Automatically approve requests of modafinil or armodafinil for members with narcolepsy when prescribed for doses at or below 200 mg of modafinil or 250 mg of armodafinil daily
- Continue to require PA for other indications and for higher doses
- Update PA criteria to approve higher doses of modafinil if lower doses are only partially effective
ACTION: Motion to approve, 2nd, all in favor

E. Hepatitis B Antivirals Class Update: Deanna Moretz, PharmD
Recommendations:
- Based on recent guidelines, make entecavir tablets preferred on the PDL
- Due to viral resistance patterns make lamivudine non-preferred on the PDL
- Revise PA criteria to only apply to nonpreferred agents
- Evaluate comparative costs in executive session
ACTION: Motion to approve, 2nd, all in favor

F. New Antibiotics for Urinary Tract Infections: Kathy Sentena, PharmD
Recommendations:
- No changes to the PDL are recommended based on review of the evidence for the new drugs for uUTI
- Maintain sulopenem/probenecid, pivmecillinam and gepotidacin as non-preferred
ACTION: Motion to approve, 2nd, all in favor

OREGON HEALTH AUTHORITY

OSU Oregon State University College of Pharmacy
Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

G. Vykat™ XR (diazoxide choline) New Drug Evaluation: Deanna Moretz, PharmD
Recommendations:
- Designate diazoxide choline extended-release tablets as non-preferred on the PDL
- Implement the Diazoxide Choline Extended-Release Tablets PA criteria to ensure appropriate use in patients with hyperphagia due to Prader-Willi syndrome
Public Comment: Mae Kwong, Soleno Therapeutics; Parisa Salehi, UW; Oliver Passemard, PWSA-USA
ACTION: The Committee recommended revising the questions to require documentation in the patient record of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) "or a comparable assessment" upon initial approval and renewal; to remove funding question and re-number as appropriate; and to document physician's assessment and a care plan instead of documenting baseline HQ-CT score
Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Samara Stevens, ND; Douglas Carr, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD; Jeanne Savage, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Antipsychotics Class
Recommendation: Make no changes to the PDL
ACTION: Motion to approve, 2nd, all in favor

B. Hepatitis B Antivirals Class
Recommendations: Make no changes to the PDL
ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN